Literature DB >> 24862131

Complement the hemostatic system: an intimate relationship.

Ilene Ceil Weitz1.   

Abstract

The complement system is important part of our innate immune system and interacts directly with the hemostatic system. Disorders of complement activation or dysregulation resulting in excess complement generation, such as Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic uremic Syndrome (aHUS) and antiphospholipid syndrome (APLS) have been associated with significant thrombophilia. Terminal Complement (C5b-9) deposition on endothelial and tumor cell membranes has also been reported in a variety of cancer. Recent developments in complement inhibition have given us new insights into the mechanism of thrombosis in these disorders.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Complement; PNH; TMA; Thrombosis

Mesh:

Substances:

Year:  2014        PMID: 24862131     DOI: 10.1016/S0049-3848(14)50020-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.

Authors:  Maria Laura Bertolaccini; Gregorio Contento; Ross Lennen; Giovanni Sanna; Philip J Blower; Michelle T Ma; Kavitha Sunassee; Guillermina Girardi
Journal:  J Autoimmun       Date:  2016-05-06       Impact factor: 7.094

Review 3.  A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis.

Authors:  Kyung-Yil Lee
Journal:  Infect Chemother       Date:  2015-03-30

Review 4.  Extra-renal manifestations of complement-mediated thrombotic microangiopathies.

Authors:  Johannes Hofer; Alejandra Rosales; Caroline Fischer; Thomas Giner
Journal:  Front Pediatr       Date:  2014-09-08       Impact factor: 3.418

5.  Elevated levels of C3, C4, and CH50 of the complement system in ICU and non-ICU patients with COVID-19.

Authors:  Ahmad Bagherimoghaddam; Houshang Rafatpanah; Hassan Mansouritorghabeh
Journal:  Health Sci Rep       Date:  2022-02-16

Review 6.  Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome.

Authors:  Jason S Knight; Yogendra Kanthi
Journal:  Semin Immunopathol       Date:  2022-02-04       Impact factor: 11.759

7.  Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.

Authors:  Catherine M Broome; Julia M Cunningham; Megan Mullins; Xiaohui Jiang; Lauren C Bylsma; Jon P Fryzek; Adam Rosenthal
Journal:  Res Pract Thromb Haemost       Date:  2020-04-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.